We serve Chemical Name:1-methoxy-3-methylsulfonylpropan-2-one CAS:728019-59-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-methoxy-3-methylsulfonylpropan-2-one
CAS.NO:728019-59-8
Synonyms:1-methoxy-3-methylsulfonylpropan-2-one
Molecular Formula:C5H10O4S
Molecular Weight:166.19500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:68.82000
Exact Mass:166.03000
LogP:0.32730
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-methoxy-3-methylsulfonylpropan-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-methoxy-3-methylsulfonylpropan-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-methoxy-3-methylsulfonylpropan-2-one Use and application,1-methoxy-3-methylsulfonylpropan-2-one technical grade,usp/ep/jp grade.
Related News: The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 1-methoxy-3-methylsulfonylpropan-2-one manufacturer Any US citizen who has been in China’s Hubei province — epicenter of the outbreak — in the last 14 days will be allowed back into the country. 1-methoxy-3-methylsulfonylpropan-2-one supplier The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 1-methoxy-3-methylsulfonylpropan-2-one vendor Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies. 1-methoxy-3-methylsulfonylpropan-2-one factory The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years.